Lorazepam
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lorazepam: From Anxiety Disorder to Trigeminal Nerve Neoplasm
One-Sentence Summary
Lorazepam is a benzodiazepine GABA-A receptor modulator, established internationally as an anxiolytic and sedative-hypnotic (Taiwan-specific licensed indication text is not available in this evidence pack — the drug is currently not marketed in Taiwan). The TxGNN model's top-ranked prediction is Trigeminal Nerve Neoplasm, but this candidate is supported by 0 clinical trials and 0 publications, and the pipeline's own mechanistic review flags it as a likely false-positive association.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Taiwan license data (lorazepam is internationally established for anxiety disorders / short-term anxiolytic and sedative use) |
| Predicted New Indication | Trigeminal Nerve Neoplasm |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L5 |
| Taiwan Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (blocking data gap). Based on known information, lorazepam is a benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, increasing chloride channel opening frequency to produce sedative, anxiolytic, and anticonvulsant effects — a well-established, class-wide mechanism rather than a novel hypothesis.
However, this specific prediction does not hold up mechanistically. There is no known relationship between GABA-A modulation and the pathophysiology of a nerve sheath neoplasm. The evidence pack's own rationale assesses this as a likely model false positive, possibly arising from data confusion between "trigeminal nerve neoplasm" and "trigeminal neuralgia" — a symptomatic pain condition for which benzodiazepines are sometimes used adjunctively, but which is pathologically unrelated to tumour growth. No clinical trial or literature signal exists to counter this assessment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Lorazepam is not currently marketed in Taiwan (0 licenses on file), so no product authorization records are available to list.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all currently unavailable — TFDA package insert extraction is a blocking data gap that prevents any S1 safety evaluation.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Trigeminal Nerve Neoplasm) has zero clinical trial or literature support, and the pipeline's mechanistic review independently assesses it as a probable model artifact rather than a genuine pharmacological signal. Combined with a blocking gap in TFDA safety data, there is no basis to advance this candidate.
To proceed, the following is needed:
- TFDA package insert extraction (warnings/contraindications) — blocking gap DG001
- DrugBank mechanism-of-action data — gap DG002
- Any preclinical or case-level evidence specifically linking GABA-A modulation to trigeminal nerve neoplasm biology (none currently found)
- Consider redirecting evaluation to the model's rank-2 candidate (insomnia, L2 evidence, 23 trials/18 publications identified, "Proceed with Guardrails"), which is far better supported by existing evidence than this top-ranked candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.